IMC Studies Part of New York Genome Center’s Polyethnic-1000 Initiative Advancing Understanding of Racial Disparities in the Prevalence of Cancer Types SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 ...
What motivated you to develop the ACE technique? One of the limitations of mass cytometry is its low sensitivity. To reach the detection limit, the target needs multiple copies of the antibody tag ...
Spatial profiling of solid tumor microenvironment using imaging mass cytometry with high-plex panels. Use of Al-based models integrating serum proteomics and clinicopathologic features to predict ...
Advancing next-generation IMC workflows with class-leading HCR imaging technologies for greater sensitivity and flexibility Molecular Instruments® (MI), the inventor of the HCR™ imaging platform, and ...
Phase 1/2 study of TSN222, a novel dual action tumor immune agonist (DATIA), in patients with advanced malignancies.
The successful use of CyTOF® technology for mass cytometry has resulted in its application in over 100 clinical research trials and a bibliography fast approaching 1,000 peer-reviewed publications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results